Pfizer Inc. $PFE Shares Sold by NBT Bank N A NY

Key Points

• NBT Bank N A NY reduced its holdings in Pfizer Inc. by 9.7%, selling 17,983 shares during the second quarter, leaving it with 167,364 shares valued at about $4.06 million.
• Several other institutional investors increased their stakes in Pfizer during the second quarter, with Abel Hall LLC raising its stake by 125.1%, while overall institutional ownership stands at 68.36%.
• Analysts have mixed views on Pfizer's stock, with an average price target of $28.41 and an overall average rating of "Hold", following various adjustments in ratings and price targets by firms like Morgan Stanley and Citigroup.

NBT Bank N A NY reduced its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 9.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 167,364 shares of the biopharmaceutical company's stock after selling 17,983 shares during the quarter. NBT Bank N A NY's holdings in Pfizer were worth $4,057,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the business. Abel Hall LLC increased its stake in Pfizer by 125.1% in the second quarter. Abel Hall LLC now owns 25,900 shares of the biopharmaceutical company's stock valued at $628,000 after purchasing an additional 14,395 shares during the last quarter. Spectrum Asset Management Inc. NB CA increased its stake in Pfizer by 3.6% in the second quarter. Spectrum Asset Management Inc. NB CA now owns 17,679 shares of the biopharmaceutical company's stock valued at $429,000 after purchasing an additional 619 shares during the last quarter. Proffitt & Goodson Inc. increased its stake in Pfizer by 23.0% in the second quarter. Proffitt & Goodson Inc. now owns 4,257 shares of the biopharmaceutical company's stock valued at $103,000 after purchasing an additional 795 shares during the last quarter. REAP Financial Group LLC increased its stake in Pfizer by 73.7% during the second quarter. REAP Financial Group LLC now owns 4,251 shares of the biopharmaceutical company's stock worth $103,000 after acquiring an additional 1,804 shares during the last quarter. Finally, Sax Wealth Advisors LLC increased its stake in Pfizer by 71.4% during the second quarter. Sax Wealth Advisors LLC now owns 19,365 shares of the biopharmaceutical company's stock worth $469,000 after acquiring an additional 8,066 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. UBS Group restated a "neutral" rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Finally, Bank of America upped their price target on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research note on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $28.41.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.27 on Wednesday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The business has a 50-day moving average of $24.76 and a 200-day moving average of $24.14. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $149.36 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 0.86 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.